WO2020013777A3 - Tablet formulations comprising metformin and sitagliptin - Google Patents

Tablet formulations comprising metformin and sitagliptin

Info

Publication number
WO2020013777A3
WO2020013777A3 PCT/TR2019/050190 TR2019050190W WO2020013777A3 WO 2020013777 A3 WO2020013777 A3 WO 2020013777A3 TR 2019050190 W TR2019050190 W TR 2019050190W WO 2020013777 A3 WO2020013777 A3 WO 2020013777A3
Authority
WO
WIPO (PCT)
Prior art keywords
sitagliptin
metformin
tablet formulations
present
surfactant
Prior art date
Application number
PCT/TR2019/050190
Other languages
French (fr)
Other versions
WO2020013777A2 (en
Inventor
Ali Turkyilmaz
Seval Ataman
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP19834733.8A priority Critical patent/EP3784672A4/en
Publication of WO2020013777A2 publication Critical patent/WO2020013777A2/en
Publication of WO2020013777A3 publication Critical patent/WO2020013777A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical tablet formulation comprising metformin and sitagliptin and at least one surfactant. Further the present invention provides a method for the preparation of said composition.
PCT/TR2019/050190 2018-04-27 2019-03-25 Tablet formulations comprising metformin and sitagliptin WO2020013777A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19834733.8A EP3784672A4 (en) 2018-04-27 2019-03-25 Tablet formulations comprising metformin and sitagliptin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201806019 2018-04-27
TR2018/06019 2018-04-27

Publications (2)

Publication Number Publication Date
WO2020013777A2 WO2020013777A2 (en) 2020-01-16
WO2020013777A3 true WO2020013777A3 (en) 2020-04-09

Family

ID=69141601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050190 WO2020013777A2 (en) 2018-04-27 2019-03-25 Tablet formulations comprising metformin and sitagliptin

Country Status (2)

Country Link
EP (1) EP3784672A4 (en)
WO (1) WO2020013777A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022074664A1 (en) * 2020-10-05 2022-04-14 V-Ensure Pharma Technologies Private Limited An immediate release composition of sitagliptin hydrochloride
KR20230009020A (en) * 2021-07-08 2023-01-17 한미약품 주식회사 A composite tablet containing sitagliptin, dapagliflozin and metformin
CN114010612B (en) * 2021-11-24 2022-06-28 上海普康药业有限公司 Sitagliptin and metformin double-layer sustained release tablet and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
WO2013110085A1 (en) * 2012-01-20 2013-07-25 Handa Pharmaceuticals, Llc Oral dosage forms for delivering metformin and sitagliptin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159203A (en) 2007-07-19 2016-12-30 Takeda Pharmaceuticals Co Solid preparation comprising alogliptin and metformin hydrochloride
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
TR201722603A2 (en) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
WO2013110085A1 (en) * 2012-01-20 2013-07-25 Handa Pharmaceuticals, Llc Oral dosage forms for delivering metformin and sitagliptin

Also Published As

Publication number Publication date
WO2020013777A2 (en) 2020-01-16
EP3784672A2 (en) 2021-03-03
EP3784672A4 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
WO2019120234A3 (en) Compound functioning as bromodomain protein inhibitor, and composition
EP3914252A4 (en) Pharmaceutical compositions of nilotinib
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin
WO2016142708A3 (en) Pharmaceutical composition
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
WO2020138791A3 (en) Sustained-release preparation comprising tofacitinib or pharmaceutically acceptable salt thereof and manufacturing method therefor
WO2019194773A3 (en) The combination comprising linagliptin and metformin
MX2020010834A (en) Solid formulation of insecticidal mixtures.
JOP20180071A1 (en) CJ Healthcare Corporation
MX2022007707A (en) Edoxaban tablets.
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
EP3760195A4 (en) Composition comprisng 2,3-butanediol as active ingredient
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP4166155A4 (en) Composition comprising pentapeptide as active ingredient
WO2015119924A3 (en) Fixed-dose combinations of antiviral compounds
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2019098572A3 (en) Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus
WO2017222819A3 (en) Solid state forms of ixazomib citrate
EP3626703A4 (en) Novel compound and pharmaceutical composition comprising same as active ingredient
ZA202201888B (en) Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19834733

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019834733

Country of ref document: EP